Glucagon-like peptide 1 agonists in cardio-oncology: is it time for a specific focus? - Top-Institutions - MDSpire

Glucagon-like peptide 1 agonists in cardio-oncology: is it time for a specific focus?

  • By

  • Teresa López-Fernández

  • Pietro Ameri

  • February 8, 2025

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Cardio-Oncology
    • Hematology
    • Endocrinology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardio-Oncology
    • Endocrinology
    • Hematology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Cardio-Oncology
    • Endocrinology

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Endocrinology
    • Oncology

Original Source(s)

Glucagon-like peptide 1 agonists in cardio-oncology: is it time for a specific focus?

  • by Teresa López-Fernández, Pietro Ameri

  • February 8, 2025

Related Content

Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure

Thoracoscopically assisted resection of left ventricular myxoma: a case report

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.